Pine Labs Ltd (PINELABS) reported its financial results for the third quarter ended December 31, 2025 (Q3 FY26), highlighting a 24% year-over-year increase in revenue from operations to \u20b9744 crore. This marks the company\u2019s third consecutive quarter of positive Profit After Tax (PAT), a significant turnaround from the net loss of \u20b9145.5 crore reported in the full fiscal year 2025.<\/p>\n\n\n\n
Adjusted EBITDA for the quarter surged 59% year-over-year to \u20b9171 crore, with margins expanding from 18% to 23%. The company processed a record Gross Transaction Value (GTV) of $51 billion during the period. Contribution margins remained robust at 77%, with management noting that 50-57% of incremental revenue now flows directly to adjusted EBITDA.<\/p>\n\n\n\n
Broader sector headwinds affecting global SaaS and software stocks, such as “seat-count” rationalization and high interest rates, have had limited impact on Pine Labs’ merchant-centric model. Instead, the company benefited from the seasonal strength of India’s festive quarter. There were no analyst rating changes reported today; however, earlier January notes from institutional desks remained focused on the bank’s successful integration of the “Setu” account aggregator license, which is expected to drive high-margin data services in 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"
Pine Labs Ltd (PINELABS) reported its financial results for the third quarter ended December 31, 2025 (Q3 FY26), highlighting a 24% year-over-year increase in revenue from operations to \u20b9744 crore. This marks the company\u2019s third consecutive quarter of positive Profit After Tax (PAT), a significant turnaround from the net loss of \u20b9145.5 crore reported in […]<\/p>\n","protected":false},"author":2386,"featured_media":178183,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,105,392,1],"tags":[14970,14969,14967,14968],"class_list":["post-178186","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-infographics","category-earnings","category-finance-stocks","tag-financial-tech-infrastructure","tag-merchant-commerce-platform","tag-offering-pos-solutions","tag-payment-processing"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":178193,"url":"https:\/\/alphastreet.com\/india\/pine-labs-ltd-pinelabs-swot-analysis\/","url_meta":{"origin":178186,"position":0},"title":"Pine Labs Ltd (PINELABS): SWOT Analysis","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"Strengths Scalable Infrastructure: Cloud-native \"Credit+\" platform allows for rapid merchant onboarding and high-volume processing. Profitability Pivot: Third consecutive quarter of positive PAT and expanding EBITDA margins (23%). Strong Liquidity: Over \u20b91,400 crore in unutilized IPO proceeds provides a significant buffer for inorganic growth. Weaknesses High Valuation: A forward P\/E exceeding\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178182,"url":"https:\/\/alphastreet.com\/india\/pine-labs-pinelabs-stock-rises-1-2-following-record-q3-revenue\/","url_meta":{"origin":178186,"position":1},"title":"Pine Labs (PINELABS) Stock Rises 1.2% Following Record Q3 Revenue","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"Shares of Pine Labs Ltd (PINELABS) traded at \u20b9231.49 on Wednesday, gaining 1.22% in intraday trading as the market absorbed third-quarter results showing sustained profitability. The stock listed on the NSE and BSE in November 2025 at \u20b9242 and has since navigated a 52-week range of \u20b9213.50 to \u20b9284.00. Today\u2019s\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178191,"url":"https:\/\/alphastreet.com\/india\/pine-labs-pinelabs-trade-exposure-and-ipo-proceeds-navigating-the-2026-regulatory-landscape\/","url_meta":{"origin":178186,"position":2},"title":"Pine Labs (PINELABS) Trade Exposure and IPO Proceeds: Navigating the 2026 Regulatory Landscape","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"As Pine Labs Ltd (PINELABS) expands its international footprint, which now accounts for 17% of total revenue, it faces increasing geopolitical and regulatory risks. The company's recent partnership with Wio Bank in the UAE and expansion into Malaysia and Australia exposes it to varying cross-border payment regulations and potential currency\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Pine_Labs-scaled.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143002,"url":"https:\/\/alphastreet.com\/india\/earnings-dr-lal-path-labs-ltd-nselalpathlab-q3fy23-results-out-total-income-fell-2-yoy\/","url_meta":{"origin":178186,"position":3},"title":"Earnings | Dr Lal Path Labs Ltd (NSE:LALPATHLAB): Q3FY23 Results Out; Total Income fell 2% YoY","author":"Divyansh_Kasana","date":"February 28, 2023","format":false,"excerpt":"Dr Lal Path Labs Ltd (NSE:LALPATHLAB) is a leading diagnostic services provider in India. The company was founded in 1949 by Dr. S.K. Lal and is currently headquartered in New Delhi, India. Dr Lal Path Labs operates a network of over 200 clinical laboratories, more than 2,600 patient service centers,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":141220,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-limited-nse-ajantapharma-q3-fy23-results-out-total-income-rises-17-yoy\/","url_meta":{"origin":178186,"position":4},"title":"Ajanta Pharma Limited (NSE: AJANTAPHARMA): Q3 FY23 Results Out; Total Income Rises 17% YoY","author":"Divyansh_Kasana","date":"February 13, 2023","format":false,"excerpt":"Ajanta Pharma Limited (NSE: AJANTAPHARMA) is an Indian pharmaceutical company that specializes in the production and distribution of generic drugs. The company has reported its financial results for the third quarter (Q3) of fiscal year 2023 (FY23) and for the first nine months (9M) of the fiscal year. The revenue\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":179436,"url":"https:\/\/alphastreet.com\/india\/saregama-india-ltd-shares-fall-as-q3-fy26-revenue-and-profit-decline\/","url_meta":{"origin":178186,"position":5},"title":"Saregama India Ltd Shares Fall as Q3 FY26 Revenue and Profit Decline","author":"Staff Correspondent","date":"February 3, 2026","format":false,"excerpt":"Saregama India Limited (SAREGAMA.NS) shares closed at \u20b9328.00 on the National Stock Exchange on Tuesday, down about 0.49% on the day, with the company\u2019s market capitalization at approximately \u20b96,305 crore at the close of trading. Saregama reported third-quarter fiscal 2026 earnings for the period ended Dec. 31, 2025, showing declines\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2386"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178186"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178186\/revisions"}],"predecessor-version":[{"id":178189,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178186\/revisions\/178189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/178183"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}